All times are listed in CEST (Central European Summer Time)
- John B. Haanen (Amsterdam, Netherlands)
- Evan J. Lipson (Baltimore, United States of America)
LBA37 - A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
- Martin H. Schuler (Essen, Germany)
Abstract
Background
Preoperative immune checkpoint inhibitor therapy (PICIT) is a promising approach in curative treatment of non-small-cell lung cancer (NSCLC). This study explores the feasibility and efficacy of targeting PD-1 and LAG-3 prior to resection.
Methods
Patients with histologically confirmed NSCLC stage IB, II or IIIA (UICC 8th edition) were randomized to receive two preoperative doses (q14d) of nivolumab (240 mg, arm A), or nivolumab (240 mg) plus relatlimab (80 mg, arm B). The primary study endpoint was the feasibility of curatively intended surgery within 43 days of start of PICIT. Secondary endpoints include pathological and radiological response rates, disease-free and overall survival rates (DFS, OS) and safety. Exploratory endpoints are addressed by translational research.
Results
From March 4, 2020 to July 15, 2022, 60 patients have been randomized. The primary endpoint was met by all patients. R0 resection rate was 98%, excluding 2 patients with pleural carcinosis, which had been undetected by preoperative imaging. PICIT-related adverse events were as expected with grade ≥ 3 events in 4 (arm A) and 2 (arm B) patients. Two patients treated in arm A died within 90 days of surgery. The 12 months OS rate across both arms was 96% (95% CI: 83-99%), the DFS rate was 91% (78-97%). Radiological response rates were 11% (arm A) and 27% (arm B) per RECIST (full population), and 41% (arm A) and 38% (B) per PERCIST (30 patients from one center). Complete or major histopathological response rates were 28% (arm A) and 32% (arm B). In 60% (arm A) and 71% (arm B) of resections after PICIT ≤ 50% vital tumor cells were observed.
Arm A (nivolumab) Arm B (nivolumab/relatlimab) 30 (15, 15) 30 (13, 17) 64 (43-77) 65 (43-81) - adenocarcinoma 13 15 - squamous 10 9 - adenosquamous 2 2 - other 5 4 - I B 9 10 - II A 6 1 - II B 11 16 - III A 3 3 - other 1 0 - 0% 8 9 - 1-49% 12 15 - ≥50% 10 6
Conclusions
Preoperative immune checkpoint inhibition with nivolumab and relatlimab is safe and feasible in patients with curatively resectable NSCLC. High histopathological response rates indicate clinical efficacy, which merits further study supplementing with biomarker analyses for future patient selection.
Clinical trial identification
NCT04205552.
Legal entity responsible for the study
University Hospital Essen.
Funding
Bristol Myers Squibb.
Disclosure
M.H.H. Schuler: Financial Interests, Personal, Invited Speaker: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Roche; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda; Financial Interests, Institutional, Research Grant: Bristol-Myers Squibb, AstraZeneca; Non-Financial Interests, Principal Investigator, Member, Study Steering Board: Janssen. K. Cuppens: Financial Interests, Personal, Advisory Board: Hoffmann-La Roche, AstraZeneca, Merck Sharp Dohme, Bristol-Myers-Squibb, Boehringer-Ingelheim, Bayer; Financial Interests, Personal, Invited Speaker: Pfizer, Bristol-Myers-Squibb, Merck Sharp Dohme, Hoffmann-La Roche; Financial Interests, Personal, Expert Testimony: Merck Sharp Dohme, AstraZeneca. T. Ploenes: Financial Interests, Personal, Invited Speaker: Roche, BMS; Financial Interests, Personal, Advisory Board: BMS, Novocure. M. Wiesweg: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Takeda; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Novartis, Pfizer, Roche; Financial Interests, Personal, Expert Testimony: GlaxoSmithKline; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Funding: Bristol-Myers Squibb. K. Darwiche: Financial Interests, Institutional, Invited Speaker: Olympus, Boston Scientific, Broncus Medical, Erbe, Böhringer Ingelheim, Storz, AstraZeneca; Financial Interests, Personal, Advisory Role: bess, Boston Scientific, Broncus Medical, Fujifilm, FreeFlow, Olympus, Storz, PulmonX, Böhringer Ingelheim, Morair Medtech, Medtronic; Financial Interests, Institutional, Research Grant: Pulmonx, PneumRx, Nuveira, Epigenomics, Broncus, Novartis, Roche, Ambu, Gala Therapeutics. A. Schramm: Financial Interests, Institutional, Funding, Funding of translational research projects outside and within clinical studies.: Bristol Myers Squibb. B. Maes: Financial Interests, Personal, Advisory Board: Servier, AstraZeneca, Illumina; Financial Interests, Personal, Invited Speaker: Pfizer, Illumina; Financial Interests, Institutional, Invited Speaker: Illumina, SeqOne; Non-Financial Interests, Principal Investigator: BSMO. H. Schildhaus: Financial Interests, Personal, Advisory Board: MSD, BMS, Roche Pharma, Novartis Oncology, AstraZeneca, Eisai, Takeda, ZytoVision, Zytomed Systems, Molecular Health; Financial Interests, Institutional, Research Grant: Novartis Oncology; Financial Interests, Personal, Full or part-time Employment: Targos Molecular Pathology Inc.. H. Hautzel: Financial Interests, Personal, Other, Travel Fees: PARI Gmbh; Financial Interests, Institutional, Research Grant: PARI Gmbh. P. Baas: Financial Interests, Institutional, Advisory Board: BMS, MSD, Beigene; Financial Interests, Institutional, Research Grant: MSD, BMS. C. Aigner: Financial Interests, Personal, Advisory Board: BMS, Roche, AstraZeneca, Biotest; Financial Interests, Personal, Invited Speaker: MSD, Roche, AstraZeneca; Financial Interests, Institutional, Invited Speaker: BMS, PharmaCept. All other authors have declared no conflicts of interest.
Invited Discussant LBA37
- Evan J. Lipson (Baltimore, United States of America)
Q&A
- All Speakers (Lugano, Switzerland)
LBA38 - BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours
- Andreas Mackensen (Erlangen, Germany)
Abstract
Background
BNT211 is a potential first-in-class therapeutic approach for claudin 6 (CLDN6)-positive solid tumors with two components: chimeric antigen receptor (CAR) T cells targeting the tumour-specific antigen CLDN6 and a CLDN6-encoding CAR T cell-Amplifying RNA Vaccine (CARVac) designed to expand adoptively transferred CAR T cells and improve their persistence.
Methods
This is a first-in-human trial (NCT04503278) in patients (pts) with CLDN6-positive relapsed/refractory solid tumours, ECOG PS 0/1 and no further standard treatment options. Following lymphodepletion, the bifurcated 3+3 design comprises CLDN6 CAR T cell dose escalations for monotherapy and combined with CLDN6 CARVac, applied repeatedly after CAR T infusion with one intra-pt dose escalation (25→50 μg). Key primary endpoint is safety and tolerability.
Results
As of 15 Jun 2022, 22 pts had been treated, mainly with testicular (13) and ovarian (4) cancers. 7 pts were treated at dose level (DL) 1 (107 CAR T cells/pt; including 1 pt with <107 cells) and 13 pts at DL2 (108 CAR T cells/pt; including 1 pt with a 50% lymphodepletion regimen and 2 pts with no lymphodepletion). 2 pts had dose-limiting toxicities: 1/6 at DL2 monotherapy (pancytopenia), and 1/7 at DL2 + CARVac (hemophagocytic lymphohistiocytosis). Most treatment-emergent adverse events ≥G2 were related to lymphodepletion or asymptomatic transaminase/lipase elevations. Cytokine release syndrome (CRS) was ≤G2, except for 1 pt with no lymphodepletion who had G3 CRS (all resolved). 7/21 evaluable pts (per RECIST v1.1, 6 wks post-infusion) had PR, 8 had SD (6 with target lesion shrinkage) and 6 had PD (including 2 deaths before assessment); as 1 pt was infused with <107 cells they were non-evaluable. 5 pts with testicular cancer responded at 6 wks, with CAR T-cell persistence and further tumour shrinkage; 1 pt was investigator-assessed as CR after 18 wks (negative PET-CT and tumour-marker negative).
Conclusions
CLDN6 CAR T cells ± CLDN6 CARVac had a manageable safety profile in this first-in-human trial, with encouraging signs of clinical activity in pts with limited treatment options.
Clinical trial identification
NCT04503278.
Editorial acknowledgement
Support for third-party writing assistance for this abstract, furnished by John Carron and Islay Steele, of Health Interactions, was provided by BioNTech Cell & Gene Therapies GmbH.
Legal entity responsible for the study
BioNTech Cell & Gene Therapies GmbH.
Funding
BioNTech Cell & Gene Therapies GmbH.
Disclosure
A. Mackensen: Financial Interests, Personal, Advisory Board: Miltenyi Biomedicine, Gilead/KITE, Novartis, BMS/Celgene, Ixaka; Financial Interests, Personal, Invited Speaker: Gilead/KITE, Novartis, BMS/Celgene; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: BMS, Ipsen, Merck Serono, Molecular Partners, MSD, Novartis, Pfizer, Roche/Genentech, Sanofi, Achilles Tx, BioNTech US, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board: Neogene Therapeutics; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Non-Financial Interests, Institutional, Funding, Grant support: Amgen, Asher Bio, BioNTech US, BMS, MSD, Novartis; Non-Financial Interests, Personal and Institutional, Member, Editor-in-Chief: ESMO IOTECH; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. C. Koenecke: Financial Interests, Personal, Advisory Board: Janssen, Novartis, BMS/Celgene, Amgen, Sanofi, EUSAPharm, Kite/Gilead, Roche, GSK, Medigene; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. W. Alsdorf: Financial Interests, Personal, Advisory Board: Janssen; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH; Financial Interests, Personal, Other, Honoraria/travel costs: Janssen, BioNTech Cell & Gene Therapies GmbH. E. Wagner-Drouet: Financial Interests, Personal, Advisory Board: Novartis, Kite/Gilead, MSD; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. D. Heudobler: Financial Interests, Personal, Advisory Board: BMS, MSD, Janssen-Cilag, Roche, Pfizer, Boehringer-Ingelheim; Financial Interests, Personal, Speaker’s Bureau: BMS, Roche, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: BMS, Janssen-Cilag; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. P. Borchmann: Other, Personal and Institutional, Sponsor/Funding: Takeda Oncology, Novartis, MSD; Other, Personal and Institutional, Principal Investigator: Miltenyi Biotech; Other, Personal, Advisory Board: Roche, Amgen; Other, Personal and Institutional, Advisory Board: Gilead; Other, Personal, Invited Speaker: BMS, Celgene, AbbVie; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. C. Bokemeyer: Financial Interests, Personal, Other, Honoraria: Merck KGaA, Sanofi, Roche, Bayer, Bristol-Myers Squibb, AstraZeneca, Merck Sharp Dohme, Berlin Chemie, Medac; Financial Interests, Personal, Advisory Board: Sanofi, Bayer Schering Pharma, Merck Sharp & Dohme, GSO, AOK Health Insurance, ODC (Oncology drug consult), Janssen-Cilag GmbH; Financial Interests, Institutional, Research Grant: AbbVie, ADC Therapeutics, Agile Therapeutics, Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, BerGenBio, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eisai, Gilead Sciences, Glycotope GmbH, GlaxoSmithKline, Incyte, IO Biotech, Isofol Medical, Janssen-Cilag, Karyopharm Therapeutics, Lilly, Millennium, MSD, Nektar, Novartis, Rafael Pharmaceuticals, Roche, Springworks Therapeutics, Taiho Pharmaceutical, BioNTech, Ipsen, Servier/Pfizer, Immatics, CPT Cellex Patient Treatment, Glycostem; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck Serono, Sanofi, Bristol-Myers Squibb, Janssen-Cilag; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. S. Klobuch: Non-Financial Interests, Institutional, Funding, Grant support: Neogene Therapeutics; Non-Financial Interests, Personal, Research Grant, Medical writing support: BioNTech Cell & Gene Therapies GmbH. E. Smit: Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. F. Müller: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS; Financial Interests, Institutional, Other, Honoraria and travel support: AstraZeneca, AbbVie, BMS, Gilead, Janssen, Novartis, Pfizer; Financial Interests, Institutional, Research Grant: Medimmune; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. A. Desuki: Financial Interests, Personal, Advisory Board: Bristol Myers-Squibb, Eisei, MSD, Bayer, Janssen-Cilag; Financial Interests, Personal, Invited Speaker: Pfizer, Bristol Myers-Squibb, Janssen-Cilag; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. F. Lüke: Financial Interests, Personal, Advisory Board: Janssen Cilag, MSD; Financial Interests, Personal, Research Grant, Grant support: Novartis; Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. E. Wiegert: Financial Interests, Personal, Other, Consultant: BioNTech, Casi, Exicure, InflaRx, iTeos therapeutics, Molecular templates, Pieris, Roche, RS Oncology, Sapience, Vyriad Inc, Schrödinger, Taiho; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. C. Flemmig: Financial Interests, Personal, Full or part-time Employment: BioNTech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. C. Schulz-Eying: Financial Interests, Personal, Full or part-time Employment: BioNTech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. B. Rengstl: Financial Interests, Personal and Institutional, Full or part-time Employment: BioNTech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE; Financial Interests, Personal, Royalties, Holds patents: BioNTech SE; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. L. Preussner: Financial Interests, Personal and Institutional, Full or part-time Employment: BioNTech SE; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. Ö. Türeci: Financial Interests, Personal and Institutional, Member of the Board of Directors, CMO: BioNTech SE; Financial Interests, Personal and Institutional, Ownership Interest, Co-founder: BioNTech SE; Financial Interests, Personal, Stocks/Shares, Co-founder: BioNTech SE; Financial Interests, Personal, Royalties, Holds patents: BioNTech SE; Other, Personal and Institutional, Leadership Role, President: CIMT; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH. U. Sahin: Financial Interests, Personal and Institutional, Member of the Board of Directors, CEO: BioNTech SE; Financial Interests, Personal and Institutional, Ownership Interest, Co-founder: BioNTech SE; Financial Interests, Personal, Stocks/Shares, Co-founder: BioNTech SE; Financial Interests, Personal, Royalties, Holds patents: BioNTech SE, TRON; Financial Interests, Institutional, Funding, TRON receives grant support from Bundesministerium für Bildung und Forshung, DFG, European Commission: TRON; Financial Interests, Personal and Institutional, Leadership Role, Scientific advisor: TRON; Non-Financial Interests, Personal, Funding, Medical writing support: BioNTech Cell & Gene Therapies GmbH.
728O - Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
- Omid Hamid (Los Angeles, United States of America)
Abstract
Background
IMC-F106C is the first TCR bispecific protein targeting CD3 and PRAME, the most broadly expressed cancer testis antigen, which is homogenously expressed in multiple tumors (eg, lung, ovarian, endometrial, melanoma, breast). ImmTAC bispecifics redirect polyclonal T cells to target intra/extracellular cancer proteins, as validated by tebentafusp (tebe; gp100×CD3 ImmTAC) with an overall survival benefit in metastatic uveal melanoma (mUM).
Methods
HLA-A*02:01+ patients (pts) with selected advanced tumors are eligible. Prospective PRAME testing required in low PRAME prevalence tumors. Primary objectives: safety and recommended dose. Secondary/exploratory objectives: efficacy, biomarkers and ctDNA response. IMC-F106C is dosed weekly with extended monitoring for intra-patient dose escalation during first 3 wks until target dose (TD).
Results
As of April 2022, 42 heavily pre-treated pts, across tumor types, were treated in 9 cohorts (TD 0.3-160 mcg) during dose escalation. 86% of tumors were confirmed PRAME+, median H score = 203. Most common (>30%) related AEs were consistent with the mechanism of action: pyrexia 64%; cytokine release syndrome (CRS) 45%; hypotension, fatigue 38% each; chills 36%; and nausea 33%. These were mostly Grade (G) 1/2, occurred in first 3 wks and rapidly resolved. 31% pts had related G3/4 AEs, most commonly lymphopenia 14% and AST increase 7%. There were no G3/4 CRS, treatment related discontinuations or deaths. Confirmed PRs were seen at TD of ≥ 20 mcg, a threshold dose for consistent and robust T cell activation. 18 pts at ≥ 20mcg were confirmed PRAME+, including 5 mUM pts who progressed on prior tebe. In 13 tebe-naïve pts, 69% (9/13) had tumor shrinkage and 38% (5/13) had a partial response (PR) including 2 of 3 cutaneous melanoma (all failed prior anti-PD1 & CTLA4), 1 of 2 ovarian, 2 of 5 mUM. All PRs are confirmed, 4 PRs ongoing. ctDNA response was observed across multiple tumor types and included some pts with complete clearance.
Conclusions
IMC-F106C, the first PRAME×CD3 ImmTAC, is well tolerated and demonstrated durable RECIST partial responses and ctDNA response in PRAME+ pts across multiple tumor types. Dose escalation and multiple expansions are ongoing.
Clinical trial identification
NCT04262466.
Legal entity responsible for the study
Immunocore Ltd.
Funding
Immunocore Ltd.
Disclosure
O. Hamid: Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pfizer, Sanofi / Regeneron; Financial Interests, Personal, Advisory Board: Aduro, Akeso, Amgen, Beigene, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi / Regeneron, Seagen, Tempus, Zelluna, Bioatla, Alkermes, Instil Bio, Iovance; Financial Interests, Institutional, Invited Speaker: Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Sanofi / Regeneron, Seagen, Torque, Zelluna, Rubius. T. Sato: Financial Interests, Personal, Advisory Role: Immunocore, Castle Biosciences; Financial Interests, Institutional, Research Grant: Immunocore, Verastem; Financial Interests, Personal, Expenses: CastleBioscience. D. Davar: Financial Interests, Institutional, Research Grant: Arcus, BMS, Checkmate Pharmaceuticals, CellSight Technologies, Merck, Tesaro/GSK; Financial Interests, Personal, Consultant: Checkmate Pharmaceuticals, Shionogi, Vedanta CE; Financial Interests, Personal, US Patent 63/124,231 / US Patent 63/208,719: Patent office. M.K. Callahan: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, ImmunoCore, AstraZeneca; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb. F. Thistlethwaite: Financial Interests, Personal, Advisory Board, honoraria: Bayer; Financial Interests, Personal, Advisory Board, Ad board: BMS, Zelluna; Financial Interests, Personal, Advisory Board, Ad boards: GSK; Financial Interests, Personal, Advisory Board, Adboard/consultancy: Tknife; Financial Interests, Personal, Advisory Board: Adicet, Janssen, EnaraBio, Immatics, Ixaka; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, iMATCH is a 12 partner consortium funded by not for profit Innovate UK (UK government body) partners include commercial, clinical and academic institutes. I am director and my salary (0.2WTE) is supported through this work as a grant to my institution (The Christie NHS foundation trust - not for profit NHS hospital) from IUK: iMATCH director; Financial Interests, Institutional, Officer, Clinical lead for this 10 partner consortium of clinical academic and commercial partners. My salary is partly supported (approx. 0.05WTE) through this by a grant paid by Innovate UK (a NFP government body) to my institution (The Christie NHS foundation trust a NFP UK hospital): SAMPLE; Financial Interests, Institutional, Invited Speaker: Pfizer, GenMab, synthon, CytomX, Incyte, Janssen, Adaptimmune, Aveo, BMS, GSK, Roche, AbbVie, Immunocore, Achilles ltd, Agalimmune Ltd, Kymab Ltd, Chugai, Millenium Pharmaceuticals/Takeda, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca; Non-Financial Interests, Panel Member for a Funding Committee (MRC is a UK government NFP organisation): MRC DPFS Panel Member. R. Aljumaily: Financial Interests, Personal, Advisory Role: Regeneron, AstraZeneca. M.L. Johnson: Financial Interests, Institutional, Research Grant: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Bioscience, Array Biopharma, Artios Pharma, AstraZeneca, Atreca, Beigene, BerGenBio, BioAtla, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, Erasca, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, OncoMed Pharmaceuticals, Pfizer, PMV Pharmaceuticals, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi , Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL, Y-mAbs Therapeutics; Financial Interests, Institutional, Advisory Role: AbbVie, Achilles Therapeutics, Amgen, AstraZeneca, Axelia Oncology, Atreca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech / Roche, Genmab, GlaxoSmithKline; Financial Interests, Institutional, : Gritstone Oncology. H. Arkenau: Financial Interests, Personal, Invited Speaker: Servier, Guardant; Financial Interests, Personal, Advisory Board: iOnctura, Beigene; Financial Interests, Institutional, Invited Speaker: multiple small and large Pharma/Biotechs. E.E. Ileana Dumbrava: Financial Interests, Institutional, Grant: Bayer HealthCare Pharmaceuticals Inc, Immunocore Ltd, Amgen, NCI, Aileron Therapeutics, Compugen Ltd, TRACON Pharmaceuticals Inc, Unum Therapeutics, Immunomedics, BOLT Therapeutics, Aprea Therapeutics, Bellicum Pharmaceuticals, PMV Pharma, Triumvira, Seagen Inc, Mereo BioPharma 5 Inc, Sanofi, Astex Therapetics ; Financial Interests, Personal, Advisory Board: BOLT Therapeutics, Mersana; Financial Interests, Personal, Advisory Role, Consultant: Catamaran Bio. B. Izar: Personal, Advisory Role: Immunocore. S. Marshall: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. Y. Yuan: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. M. Deo: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. S. Stanhope: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. L. Collins: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. R. Mundy: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. S.E. Abdullah: Financial Interests, Personal, Full or part-time Employment: Immunocore; Financial Interests, Personal, Stocks/Shares: Immunocore. J.S. Lopez: Financial Interests, Personal, Research Grant: Roche Genentech, Basilea, Genmab; Financial Interests, Personal, Advisory Board: Basilea, Ellipses. All other authors have declared no conflicts of interest.
Invited Discussant LBA38 TBC and 728O
- David A. Braun (New Haven, United States of America)
Q&A
- All Speakers (Lugano, Switzerland)